These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38251744)

  • 21. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
    Arora S; Balasubramaniam S; Zhang W; Zhang L; Sridhara R; Spillman D; Mathai JP; Scott B; Golding SJ; Coory M; Pazdur R; Beaver JA
    Clin Cancer Res; 2020 Oct; 26(19):5062-5067. PubMed ID: 32295834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
    Makker V; Taylor MH; Aghajanian C; Cohn AL; Brose MS; Simone CD; Cao ZA; Suttner L; Loboda A; Cristescu R; Jelinic P; Orlowski R; Dutta L; Matsui J; Dutcus CE; Minoshima Y; Messing MJ
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
    Kawazoe A; Fukuoka S; Nakamura Y; Kuboki Y; Wakabayashi M; Nomura S; Mikamoto Y; Shima H; Fujishiro N; Higuchi T; Sato A; Kuwata T; Shitara K
    Lancet Oncol; 2020 Aug; 21(8):1057-1065. PubMed ID: 32589866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
    Zammarrelli WA; Ma W; Espino K; Gordhandas S; Yeoshoua E; Ehmann S; Zhou Q; Iasonos A; Abu-Rustum NR; Aghajanian C; Green AK; Rubinstein MM; Makker V
    Gynecol Oncol; 2023 Nov; 178():27-35. PubMed ID: 37748268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer].
    De Jesus C; Rodrigues M
    Bull Cancer; 2022; 109(7-8):740-741. PubMed ID: 35672187
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
    J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
    Makker V; Colombo N; Casado Herráez A; Monk BJ; Mackay H; Santin AD; Miller DS; Moore RG; Baron-Hay S; Ray-Coquard I; Ushijima K; Yonemori K; Kim YM; Guerra Alia EM; Sanli UA; Bird S; Orlowski R; McKenzie J; Okpara C; Barresi G; Lorusso D
    J Clin Oncol; 2023 Jun; 41(16):2904-2910. PubMed ID: 37058687
    [No Abstract]   [Full Text] [Related]  

  • 28. Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea.
    Kim J; Noh JJ; Lee TK; Kim SI; Lee JY; Lee JW; Kim JW
    Gynecol Oncol; 2022 May; 165(2):369-375. PubMed ID: 35277278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
    Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
    Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
    Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H
    Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab.
    Bernard L; How JA; Patel S; Yates MS; Jazaeri A
    Gynecol Oncol; 2024 Jan; 180():139-145. PubMed ID: 38091773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study.
    Shang X; Su H; Chen X; Wang Y; Wan X; Zhang Y; Jin Y; Feng F
    Int J Gynecol Cancer; 2024 Aug; 34(8):1203-1210. PubMed ID: 38658019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
    Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
    Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis.
    Feng M; Chen Y; Yang Y; Li Q
    Front Public Health; 2022; 10():881034. PubMed ID: 35619813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
    Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
    Eskander RN; Sill MW; Beffa L; Moore RG; Hope JM; Musa FB; Mannel R; Shahin MS; Cantuaria GH; Girda E; Mathews C; Kavecansky J; Leath CA; Gien LT; Hinchcliff EM; Lele SB; Landrum LM; Backes F; O'Cearbhaill RE; Al Baghdadi T; Hill EK; Thaker PH; John VS; Welch S; Fader AN; Powell MA; Aghajanian C
    N Engl J Med; 2023 Jun; 388(23):2159-2170. PubMed ID: 36972022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not.
    Paulino E
    Int J Gynecol Cancer; 2022 Apr; 32(4):579. PubMed ID: 35190462
    [No Abstract]   [Full Text] [Related]  

  • 40. Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer.
    Swift BE; Gien LT
    Curr Treat Options Oncol; 2022 Aug; 23(8):1121-1134. PubMed ID: 35793055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.